Trial Profile

A Phase 1b Study of 177Lu-PSMA-617 Combined With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
Indications Liver metastases; Prostate cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

23 Mar 2026 Planned initiation date changed from 31 Jan 2026 to 16 Mar 2026.
23 Mar 2026 Status changed from not yet recruiting to recruiting.
18 Dec 2025 Planned End Date changed from 31 Aug 2030 to 31 Oct 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com